{"id":58947,"date":"2026-03-06T16:29:03","date_gmt":"2026-03-06T08:29:03","guid":{"rendered":"https:\/\/flcube.com\/?p=58947"},"modified":"2026-03-06T16:29:04","modified_gmt":"2026-03-06T08:29:04","slug":"sciwinds-ecnoglutide-wins-nmpa-approval-for-weight-loss-worlds-first-camp-biased-glp-1-agonist-targets-china-obesity-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58947","title":{"rendered":"Sciwind’s Ecnoglutide Wins NMPA Approval for Weight Loss \u2013 World’s First cAMP-Biased GLP-1 Agonist Targets China Obesity Market"},"content":{"rendered":"\n

Sciwind Biosciences<\/strong> announced that Ecnoglutide injection (Xianweiying)<\/strong>, the world’s first cAMP-biased GLP-1 receptor agonist<\/strong>, has received NMPA approval<\/strong> for long-term weight management<\/strong> in adults who are overweight or obese. The approval marks the first cAMP-biased GLP-1RA weight-loss drug globally<\/strong>, with clinical data showing 15.4% average weight loss<\/strong> over 48 weeks and 92.8% of patients achieving clinically siganificant reduction<\/strong>, positioning Sciwind to capture share of China’s rapidly expanding metabolic disease market.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Approval Date<\/strong><\/td>6\u202fMar\u202f2026<\/td><\/tr>
Product<\/strong><\/td>Ecnoglutide injection (Xianweiying)<\/td><\/tr>
Drug Class<\/strong><\/td>cAMP-biased GLP-1 receptor agonist (first-in-class globally)<\/td><\/tr>
Indication<\/strong><\/td>Long-term weight management (overweight\/obese adults)<\/td><\/tr>
Mechanism<\/strong><\/td>Biased signaling preferentially activating cAMP pathway<\/td><\/tr>
Prior Approval<\/strong><\/td>Type 2 diabetes (30\u202fJan\u202f2026) \u2013 world’s first cAMP-biased GLP-1RA approval<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Efficacy Data<\/h2>\n\n\n\n
Endpoint<\/th>Result<\/th>Significance<\/th><\/tr><\/thead>
Mean Weight Loss (48 weeks)<\/strong><\/td>15.4%<\/td>Superior to placebo and many marketed GLP-1RAs<\/td><\/tr>
Placebo-Corrected Weight Loss<\/strong><\/td>15.1%<\/td>Robust effect size in Chinese population<\/td><\/tr>
Responder Rate (\u22655% weight loss)<\/strong><\/td>92.8%<\/td>High patient compliance and clinical relevance<\/td><\/tr>
Adjunct Therapy<\/strong><\/td>Reduced-calorie diet + increased physical activity<\/td>Standard of care combination<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Product Differentiation & Manufacturing<\/h2>\n\n\n\n
Attribute<\/th>Ecnoglutide Advantage<\/th><\/tr><\/thead>
Molecular Design<\/strong><\/td>cAMP-biased signaling vs. balanced GLP-1R agonism (semaglutide, tirzepatide)<\/td><\/tr>
Clinical Profile<\/strong><\/td>Enhanced efficacy with potentially improved tolerability via pathway selectivity<\/td><\/tr>
Manufacturing<\/strong><\/td>Superior scalability vs. peptide-based competitors; recombinant production platform<\/td><\/tr>
Dosing<\/strong><\/td>Injection formulation; dosing frequency competitive with once-weekly standards<\/td><\/tr>
IP Position<\/strong><\/td>Independently developed by Sciwind; global patent estate<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Commercial Strategy & Partnership<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
China Commercial Rights<\/strong><\/td>Pfizer<\/strong> (exclusive license agreement, Feb\u202f2026)<\/td><\/tr>
Pfizer Role<\/strong><\/td>Exclusive commercialization in Mainland China<\/td><\/tr>
Sciwind Retains<\/strong><\/td>Manufacturing supply, ex-China rights, pipeline expansion<\/td><\/tr>
Launch Timing<\/strong><\/td>Immediate availability; NRDL negotiation for 2026 reimbursement<\/td><\/tr>
Target Market<\/strong><\/td>200+ million overweight\/obese adults in China; GLP-1 penetration still <5%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Competitive Landscape<\/h2>\n\n\n\n
Competitor<\/th>Product<\/th>Mechanism<\/th>Ecnoglutide Differentiation<\/th><\/tr><\/thead>
Novo Nordisk<\/strong><\/td>Wegovy (semaglutide)<\/td>Balanced GLP-1RA<\/td>cAMP bias may offer superior efficacy\/tolerability ratio<\/td><\/tr>
Eli Lilly<\/strong><\/td>Zepbound (tirzepatide)<\/td>GLP-1\/GIP dual agonist<\/td>Single-target cAMP bias vs. multi-target; manufacturing cost advantage<\/td><\/tr>
Sciwind<\/strong><\/td>Xianweiying<\/strong> (ecnoglutide)<\/td>cAMP-biased GLP-1RA<\/strong><\/td>First-in-class mechanism; China-approved before U.S.\/EU<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Outlook<\/h2>\n\n\n\n